NPI: 1003821729 · HUNTINGTON, IN 46750 · Institutional Pharmacy · NPI assigned 07/30/2006
Authorized official RISSER, STANTON controls 20+ related entities in our dataset. Read more
| Authorized Official | RISSER, STANTON (ACFO) |
| Parent Organization | HUNTINGTON MEMORIAL HOSPITAL, INC. |
| NPI Enumeration Date | 07/30/2006 |
Other providers sharing the same authorized official: RISSER, STANTON
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 17,530 | $301K |
| 2019 | 16,868 | $696K |
| 2020 | 15,278 | $741K |
| 2021 | 19,086 | $1.13M |
| 2022 | 22,962 | $1.67M |
| 2023 | 18,414 | $1.23M |
| 2024 | 10,427 | $727K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 18,357 | 16,283 | $3.23M |
| 99284 | Emergency department visit for the evaluation and management, high severity | 7,266 | 5,990 | $1.01M |
| 41899 | Unlisted procedure, dentoalveolar structures | 214 | 203 | $437K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2,308 | 741 | $269K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3,484 | 2,806 | $192K |
| 71045 | Radiologic examination, chest; single view | 1,395 | 1,150 | $172K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 645 | 448 | $114K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 543 | 500 | $98K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 625 | 210 | $83K |
| 71046 | Radiologic examination, chest; 2 views | 464 | 421 | $69K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 140 | 84 | $68K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 511 | 136 | $63K |
| 80048 | Basic metabolic panel (calcium, ionized) | 13,679 | 11,159 | $59K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 808 | 495 | $55K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 12,719 | 10,483 | $54K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 149 | 123 | $53K |
| 36415 | Collection of venous blood by venipuncture | 21,095 | 17,548 | $46K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 703 | 618 | $43K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,477 | 1,264 | $39K |
| 70450 | Computed tomography, head or brain; without contrast material | 377 | 298 | $37K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 486 | 452 | $35K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 539 | 463 | $23K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 336 | 306 | $21K |
| 80061 | Lipid panel | 2,603 | 2,342 | $18K |
| 80076 | 4,232 | 3,588 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1,736 | 1,539 | $15K |
| 84484 | 2,105 | 1,619 | $12K | |
| 99221 | 31 | 27 | $10K | |
| 99238 | Hospital discharge day management, 30 minutes or less | 32 | 28 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 271 | 248 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 271 | 248 | $8K |
| 99219 | 16 | 12 | $8K | |
| 87660 | 414 | 381 | $8K | |
| 87510 | 414 | 381 | $7K | |
| 87480 | 414 | 381 | $7K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1,400 | 1,229 | $7K |
| 83690 | 2,237 | 1,872 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 133 | 122 | $6K |
| 85027 | 1,709 | 1,412 | $5K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 468 | 436 | $5K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 108 | 101 | $5K |
| 83735 | 1,571 | 1,331 | $5K | |
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 14 | 12 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | 33 | 26 | $4K |
| 81001 | 2,338 | 1,982 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 366 | 308 | $4K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 48 | 46 | $4K |
| 80053 | Comprehensive metabolic panel | 528 | 431 | $4K |
| 99217 | 16 | 12 | $3K | |
| 73630 | 98 | 76 | $3K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 165 | 140 | $3K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 19 | 12 | $3K |
| 96361 | Intravenous infusion, hydration; each additional hour | 55 | 36 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 13 | 13 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 14 | 12 | $1K |
| 81025 | 213 | 191 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 270 | 223 | $1K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 117 | 106 | $1K |
| 87800 | 32 | 28 | $1K | |
| 80320 | 15 | 12 | $1K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 18 | 16 | $1K |
| 86850 | 139 | 130 | $840.13 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 43 | 36 | $720.89 |
| 85014 | 167 | 154 | $434.72 | |
| 85018 | 167 | 154 | $434.72 | |
| 86901 | 143 | 131 | $368.24 | |
| 86900 | 140 | 131 | $358.78 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 12 | 12 | $312.17 |
| 84460 | 116 | 102 | $300.90 | |
| 83880 | 12 | 12 | $274.82 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 25 | 24 | $253.28 |
| 86592 | 71 | 68 | $239.62 | |
| 82077 | 18 | 14 | $217.75 | |
| 82150 | 46 | 42 | $193.80 | |
| 86140 | 27 | 26 | $135.48 | |
| 85379 | 15 | 15 | $132.34 | |
| 80051 | 101 | 98 | $121.62 | |
| 85610 | 69 | 51 | $95.82 | |
| 82565 | 105 | 102 | $88.90 | |
| 87081 | 12 | 12 | $80.16 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 42 | 41 | $73.71 |
| 82947 | 28 | 28 | $70.56 | |
| 84520 | 101 | 98 | $68.44 | |
| 81003 | 41 | 26 | $60.71 | |
| 84450 | 12 | 12 | $25.02 | |
| A0425 | Ground mileage, per statute mile | 3,390 | 2,519 | $4.00 |
| A0429 | Ambulance service, basic life support, emergency transport (bls-emergency) | 1,092 | 850 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 221 | 162 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 111 | 93 | $0.00 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 333 | 281 | $0.00 |
| A0427 | Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) | 548 | 468 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 15 | 12 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 290 | 245 | $0.00 |
| 81514 | 43 | 42 | $0.00 | |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 13 | 12 | $0.00 |